# How Regeneron Pharmaceuticals (REGN) compares with the whole market and its popular alternatives

> Source: EasyCompare research, https://easycompare.io/research/regn
> Data as of October 20, 2026. Total returns include reinvested dividends. Past performance does not predict future results; nothing here is investment advice.

Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on REGN alone. It places REGN (Regeneron Pharmaceuticals, Inc.) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where REGN stands in the market, and of the alternatives worth a closer look.

Period covered: REGN's full trading record, from April 1991 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.

## Key findings

- **Right now:** The slide is REGN's own: it is 32.2% below its high, against 1.3% for the S&P 500. On the flip side, REGN has run far ahead of the market, rising 20.3% over the past 3 months against 3.9% for the S&P 500 and 3.2% for the Nasdaq 100.
- **Stock or market?:** REGN's 20.3% gain over the past 3 months far outran its industry: the biotechnology ETF XBI (State Street SPDR S&P Biotech ETF) rose 1.5%. The S&P 500 rose 3.9%. Its biotechnology peers did not move as one over the past 3 months: HALO (Halozyme Therapeutics) rose 61.3%, while ARGX (argenx) rose 2.8%.
- **Past 1 to 3 years:** Over the past year, REGN rose 40.7% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. Even so, REGN led its biotechnology peers in 2023, then fell behind AMGN (Amgen) and BIIB (Biogen) in 2025.
- **Long term:** REGN turned $10,000 into $22,000 over the past decade, against $42,100 in the S&P 500.
- **In a crash:** Across seven sell-offs, REGN has typically fallen 1.3 times as far as the S&P 500.
- **Diversification:** REGN is a real diversifier: a correlation of 0.08 with the S&P 500 over 5 years and 0.07 with the total US market, less closely than 96% of stocks worth at least $300 million. On the flip side, over 10 years, REGN's beta versus the S&P 500 was 0.19: 55% of the S&P 500's gains in rising months and 66% of its losses in falling ones.
- **Better options**
  - **Nearby categories and themes:** MRK (Merck & Co., Inc., pharmaceuticals) and TAK (Takeda Pharmaceutical, pharmaceuticals) earned more than REGN with less volatility over the past 5 years. MRK returned 16.3% a year at 24.8% volatility, against 7.7% a year at 31.1%.
  - **Whole market:** 688 of the 3,633 stocks and funds worth at least $500 million earned more than REGN with less volatility over the past 5 years, among them AAPL (Apple), MSFT (Microsoft) and VTI (Vanguard Morningstar Total Stock Market ETF).

## How much would $10,000 in REGN have grown?

This chart tracks a hypothetical $10,000 investment in REGN over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of REGN over the same span and REGN's popular alternatives, among those that traded for the entire period.

- $10,000 invested in REGN at the end of September 1997 would have grown to $683,800 by September 2026, more than the $132,907 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of REGN, and AAPL finished highest, at $20,534,853.

## REGN at a glance

This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout.

- REGN is still 32.2% below its all-time high.
- REGN's deepest decline since it began trading in 1991 was 91.8%, from February 2000 to April 2005. It took about six years from the low to climb back to its old high.
- Over 29 full calendar years, REGN's best was 2012, when it returned 209%, and its worst was 1997, when it lost 46.9%. It lost money in ten of those years.

- Type: Stock, Healthcare (Biotechnology)
- Trading since: April 2, 1991
- Market value: $83B
- Volatility (5 years): 31.1%; Sharpe ratio: 0.40
- Worst decline ever: −91.8%, from February 29, 2000 to April 14, 2005; back at its high by April 27, 2011

| Period | REGN total return |
| --- | --- |
| 1 month | +1.2% |
| 3 months | +20.3% |
| 6 months | +8.0% |
| year to date | +4.4% |
| 1 year | +40.7% |
| 3 years | +0.8% |
| 5 years | +44.9% |
| 10 years | +120% |

## REGN against the whole market

Where REGN ranks among every stock and fund, and what across the market has done better.

### How does REGN rank among all stocks?

This section ranks REGN on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history.

- REGN's 3-year return ranks in the bottom 23% of the 3,017 stocks worth at least $300 million with 3 years of history.
- REGN's 1-year return ranks in the top 22% of the 3,287 stocks worth at least $300 million with 1 year of history.

| Measure | REGN | Rank |
| --- | --- | --- |
| 1-year return | +40.7% | 718 of 3,287 (top 22%) |
| 3-year return | +0.8% | 2,316 of 3,017 (top 77%) |
| 5-year return | +44.9% | 1,149 of 2,893 (top 40%) |
| 10-year return | +120% | 1,239 of 2,202 (top 57%) |
| Volatility, 5 years | 31.1% | 837 of 2,893 (top 29%) |
| Sharpe ratio, 5 years | 0.40 | 1,245 of 2,893 (top 44%) |
| Worst decline, past 10 years | −59.7% | 866 of 2,187 (top 40%) |

### What has beaten REGN on both return and risk?

Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer).

- 271 stocks and 417 ETFs worth at least $500 million sit in the green region: each earned more than REGN over the past 5 years with smaller price swings. That is 19% of the 3,633 screened.
- Among those with at least half REGN's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 21% less than REGN's 31.1%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.40 for REGN.
- Among REGN's popular alternatives, GILD, VRTX and AMGN are in the region. GILD earned 22.8% a year against 7.7% a year for REGN, at 24.9% volatility, 20% less than REGN's 31.1%.

### Is there a better investment than REGN?

The table below lists investments that beat REGN over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes.

- Among REGN's popular alternatives, AMGN, GILD and VRTX earned more than REGN with less volatility over the past 5 years. AMGN returned 19.6% a year at 24.9% volatility, against 7.7% a year at 31.1%.
- Looking beyond its popular alternatives, MRK (pharmaceuticals) and TAK (pharmaceuticals) earned more than REGN with less volatility over the past 5 years. MRK returned 16.3% a year at 24.8% volatility, against 7.7% a year at 31.1%.
- Across the whole market, 688 of the 3,633 stocks and funds worth at least $500 million earned more than REGN with less volatility over the past 5 years, among them AAPL, MSFT and VTI.

The 15 strongest of 688 investments that beat REGN over the past 5 years, out of 3,633 stocks and funds worth at least $500 million.

| Investment | Group | Annual return (5 years) | Volatility | Sharpe | Worst decline (10 years) | 10Y return | Correlation with REGN | Better on |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| REGN: Regeneron Pharmaceuticals, Inc. (this page) |  | +7.7% | 31.1% | 0.40 | −59.7% | +120% |  |  |
| [CAH](https://easycompare.io/research/cah): Cardinal Health, Inc. | Health Care Distribution | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.11 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [MSFT](https://easycompare.io/research/msft): Microsoft Corporation | Software | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.08 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [CSCO](https://easycompare.io/research/csco): Cisco Systems, Inc. | Communications Equipment | +16.8% | 26.1% | 0.73 | −42.0% | +374% | -0.08 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [MCK](https://easycompare.io/research/mck): McKesson Corporation | Health Care Distribution | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.17 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [TD](https://easycompare.io/research/td): The Toronto-Dominion Bank | Banks | +15.8% | 20.0% | 0.84 | −42.0% | +310% | 0.01 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [SMFG](https://easycompare.io/research/smfg): Sumitomo Mitsui Financial Group, Inc. | Banks | +33.7% | 29.4% | 1.14 | −47.6% | +474% | -0.05 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [TRV](https://easycompare.io/research/trv): The Travelers Companies, Inc. | Property & Casualty Insurance | +22.4% | 22.3% | 1.02 | −46.3% | +347% | 0.21 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [BNS](https://easycompare.io/research/bns): The Bank of Nova Scotia | Banks | +12.9% | 19.9% | 0.71 | −46.9% | +187% | 0.08 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [IX](https://easycompare.io/research/ix): ORIX Corporation | Diversified Financials | +17.9% | 25.4% | 0.78 | −42.5% | +284% | 0.11 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| SDCI: USCF SummerHaven Dynamic Commodity Strategy No K-1 Fund | Bonds | +20.6% | 18.4% | 1.12 | −45.7% | — | 0.07 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [FMX](https://easycompare.io/research/fmx): Fomento Económico Mexicano, S.A.B. de C.V. | Convenience Stores | +14.0% | 25.7% | 0.64 | −45.5% | +79.7% | 0.08 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| RS: Reliance Steel & Aluminum Co. | Metals & Mining | +24.8% | 28.1% | 0.93 | −40.8% | +626% | 0.04 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| EXPD: Expeditors International of Washington, Inc. | Freight & Logistics | +12.0% | 27.1% | 0.56 | −35.6% | +349% | 0.20 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [MRK](https://easycompare.io/research/mrk): Merck & Co., Inc. | Pharmaceuticals | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.42 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| RNR: RenaissanceRe Holdings Ltd. | Insurance | +20.1% | 27.8% | 0.80 | −40.7% | +215% | 0.18 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |

## REGN against its popular alternatives

The investments people most often weigh against REGN, compared period by period and year by year.

### How do REGN's risk and return compare with its alternatives?

This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings.

- Four of the 22 popular alternatives, led by GILD, VRTX and AMGN, were both more rewarding and calmer than REGN over the past 5 years, earning a higher annual return with lower volatility.
- Over the past 5 years, REGN returned 7.7% a year, less than the S&P 500's 12.7%, with higher volatility (31.1% against 17.1%).

### Has REGN consistently beaten its popular alternatives?

This section compares REGN with the investments people most often weigh against it, checking each one over eight periods from one month to ten years.

- Seven of the 22 popular alternatives, led by HALO, AMGN and LLY, outperformed REGN in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- HALO, AMGN and LLY outperformed REGN in every long-term period and in all but one short-term period, the most consistent record in the group.
- LLY, GILD and VRTX earned more for the risk they took than REGN (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.

| Investment | 1Y return | 3Y return | 5Y return | 10Y return | Periods ahead of REGN | Verdict | Sharpe |
| --- | --- | --- | --- | --- | --- | --- | --- |
| REGN: Regeneron Pharmaceuticals, Inc. (this page) | +40.7% | +0.8% | +44.9% | +120% |  |  | 0.40 |
| HALO: Halozyme Therapeutics, Inc. | +87.1% | +254% | +226% | +1,196% | 5/5 short-term, 3/3 long-term | all-weather | 0.79 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | +48.7% | +72.2% | +145% | +266% | 5/5 short-term, 3/3 long-term | all-weather | 0.85 |
| [LLY](https://easycompare.io/research/lly): Eli Lilly and Company | +59.7% | +124% | +451% | +1,807% | 4/5 short-term, 3/3 long-term | all-weather | 1.21 |
| EXEL: Exelixis, Inc. | +86.4% | +205% | +198% | +448% | 4/5 short-term, 3/3 long-term | all-weather | 0.79 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | +30.3% | +121% | +180% | +200% | 3/5 short-term, 3/3 long-term | consistent | 0.95 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | +26.8% | +49.5% | +15.1% | +366% | 4/5 short-term, 2/3 long-term | consistent | 0.24 |
| PCVX: Vaxcyte, Inc. | +54.4% | +41.5% | +197% | — | 3/5 short-term, 2/3 long-term | consistent | 0.65 |
| [VRTX](https://easycompare.io/research/vrtx): Vertex Pharmaceuticals Incorporated | +22.8% | +42.2% | +177% | +521% | 2/5 short-term, 3/3 long-term |  | 0.85 |
| UTHR: United Therapeutics Corporation | +28.0% | +146% | +188% | +390% | 2/5 short-term, 3/3 long-term |  | 0.78 |
| PTCT: PTC Therapeutics, Inc. | −8.0% | +171% | +75.4% | +796% | 0/5 short-term, 3/3 long-term |  | 0.48 |
| [DHR](https://easycompare.io/research/dhr): Danaher Corporation | +8.3% | +10.8% | −17.6% | +232% | 2/5 short-term, 2/3 long-term |  | 0.01 |
| INCY: Incyte Corporation | +35.3% | +112% | +77.6% | +31.8% | 2/5 short-term, 2/3 long-term |  | 0.53 |
| ALNY: Alnylam Pharmaceuticals, Inc. | −53.0% | +42.6% | +13.2% | +514% | 0/5 short-term, 2/3 long-term |  | 0.29 |
| NBIX: Neurocrine Biosciences, Inc. | +0.5% | +28.6% | +37.4% | +211% | 0/5 short-term, 2/3 long-term |  | 0.36 |
| [ARGX](https://easycompare.io/research/argx): argenx SE | +2.4% | +83.1% | +194% | — | 0/5 short-term, 2/3 long-term |  | 0.74 |
| IONS: Ionis Pharmaceuticals, Inc. | −38.3% | −1.6% | +48.8% | +58.8% | 0/5 short-term, 1/3 long-term |  | 0.40 |
| BIIB: Biogen Inc. | +65.8% | −5.6% | −8.8% | −18.9% | 5/5 short-term, 0/3 long-term |  | 0.11 |
| RARE: Ultragenyx Pharmaceutical Inc. | −53.4% | −51.6% | −79.2% | −75.9% | 1/5 short-term, 0/3 long-term |  | -0.22 |
| [SNY](https://easycompare.io/research/sny): Sanofi | −13.4% | −10.0% | +3.0% | +61.5% | 0/5 short-term, 0/3 long-term |  | 0.15 |
| BMRN: BioMarin Pharmaceutical Inc. | +6.3% | −31.3% | −24.9% | −33.0% | 0/5 short-term, 0/3 long-term |  | -0.01 |
| SRPT: Sarepta Therapeutics, Inc. | −16.8% | −82.8% | −76.0% | −60.9% | 0/5 short-term, 0/3 long-term |  | -0.03 |
| BNTX: BioNTech SE | −15.5% | +0.3% | −65.7% | — | 0/5 short-term, 0/3 long-term |  | -0.15 |

### How did REGN do year by year?

This table shows each investment's total return in every full calendar year since 1997, along with where REGN ranked among its popular alternatives each year.

- REGN finished ahead of the S&P 500 in 17 of its 29 full calendar years, and behind it in each of the last three.
- Among its popular alternatives, ARGX came out ahead of REGN most often, in five of the eight years both traded.
- Ranked against its popular alternatives each year, REGN finished in the top quarter in seven of 29 years and in the bottom quarter in five. In 2025, it ranked 15 of 23.

| Year | REGN | SPY |
| --- | --- | --- |
| 2025 | +9.0% | +17.7% |
| 2024 | −18.9% | +24.9% |
| 2023 | +21.7% | +26.2% |
| 2022 | +14.2% | −18.2% |
| 2021 | +30.7% | +28.7% |
| 2020 | +28.7% | +18.3% |
| 2019 | +0.5% | +31.2% |
| 2018 | −0.7% | −4.6% |
| 2017 | +2.4% | +21.7% |
| 2016 | −32.4% | +12.0% |

## Risk and diversification

How REGN has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.

### What were REGN's worst declines?

A drawdown is the decline from a peak to the lowest point before a new high.

- In all four of REGN's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: REGN fell 77.4% from October 1996 to April 1999, while the S&P 500 rose 96.7%.
- The slowest recovery came after REGN fell 91.8% from February 2000 to April 2005; it did not regain that peak until April 2011, six years later.

| Decline | Peak | Low | Back at the high | SPY over the same dates | Market event |
| --- | --- | --- | --- | --- | --- |
| −91.8% | February 29, 2000 | April 14, 2005 | April 27, 2011 | −8.9% | dot-com bust |
| −86.7% | February 6, 1992 | December 30, 1994 | October 4, 1996 | — |  |
| −77.4% | October 8, 1996 | April 7, 1999 | February 23, 2000 | +96.7% |  |
| −59.7% | August 27, 2024 | June 5, 2025 | not yet | +6.6% |  |
| −53.8% | August 5, 2015 | September 27, 2019 | May 29, 2020 | +53.0% | 2015 China and oil sell-off |

### How did REGN do in stock market crashes?

This section measures how far REGN, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000.

- Among its popular alternatives, AMGN held up best, falling less than REGN in seven of the ten crashes they both traded through.
- REGN fell further than the S&P 500 in six of the ten crashes it has traded through. The clearest case was the 2015 China and oil sell-off, when REGN fell 37.7% and the S&P 500 fell 12.8%.

| Crash | Dates | REGN fall | SPY fall |
| --- | --- | --- | --- |
| Dot-com bust | March 10, 2000 to October 9, 2002 | −71.6% | −47.5% |
| Global financial crisis | October 9, 2007 to March 9, 2009 | −49.9% | −55.2% |
| Flash crash | May 6, 2010 to May 7, 2010 | −7.2% | −1.5% |
| Euro debt crisis | July 22, 2011 to October 3, 2011 | −23.2% | −17.9% |
| China devaluation & oil rout | August 10, 2015 to February 11, 2016 | −37.7% | −12.8% |
| Volmageddon | February 2, 2018 to February 9, 2018 | −7.3% | −6.5% |
| Q4 2018 selloff | September 21, 2018 to December 24, 2018 | −17.3% | −19.3% |
| COVID crash | February 19, 2020 to March 23, 2020 | −12.7% | −33.7% |
| 2022 bear market | January 4, 2022 to October 12, 2022 | −25.8% | −24.5% |
| SVB / regional bank stress | March 8, 2023 to March 13, 2023 | −0.2% | −3.4% |

### How closely does REGN move with the S&P 500?

Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell.

- Over the past 10 years, REGN captured 55% of the S&P 500's gains in rising months and 66% of its losses in falling months, with a beta of 0.19. Its share of the market's losses was larger than its share of the gains.
- 12 of the 19 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than REGN's 0.84, led by LLY, VRTX and EXEL.
- LLY took just 6% of the S&P 500's losses, against 66% for REGN, while still keeping 101% of its gains.

Measured over the past 10 years of monthly returns against SPY.

| Investment | Upside capture | Downside capture | Beta |
| --- | --- | --- | --- |
| REGN: Regeneron Pharmaceuticals, Inc. (this page) | 55.0% | 66.0% | 0.19 |
| HALO: Halozyme Therapeutics, Inc. | 129% | 102% | 1.15 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | 74.0% | 64.0% | 0.54 |
| [LLY](https://easycompare.io/research/lly): Eli Lilly and Company | 101% | 6.0% | 0.37 |
| EXEL: Exelixis, Inc. | 74.0% | 43.0% | 0.73 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | 52.0% | 36.0% | 0.35 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | 104% | 104% | 0.81 |
| [VRTX](https://easycompare.io/research/vrtx): Vertex Pharmaceuticals Incorporated | 87.0% | 50.0% | 0.46 |
| UTHR: United Therapeutics Corporation | 75.0% | 45.0% | 0.52 |
| PTCT: PTC Therapeutics, Inc. | 112% | 115% | 0.85 |
| [DHR](https://easycompare.io/research/dhr): Danaher Corporation | 84.0% | 84.0% | 0.75 |
| INCY: Incyte Corporation | 52.0% | 87.0% | 0.77 |
| ALNY: Alnylam Pharmaceuticals, Inc. | 92.0% | 93.0% | 0.73 |
| NBIX: Neurocrine Biosciences, Inc. | 69.0% | 66.0% | 0.56 |
| IONS: Ionis Pharmaceuticals, Inc. | 71.0% | 125% | 0.74 |
| BIIB: Biogen Inc. | 35.0% | 91.0% | 0.28 |
| RARE: Ultragenyx Pharmaceutical Inc. | 19.0% | 142% | 1.07 |
| [SNY](https://easycompare.io/research/sny): Sanofi | 53.0% | 74.0% | 0.46 |
| BMRN: BioMarin Pharmaceutical Inc. | 20.0% | 70.0% | 0.38 |
| SRPT: Sarepta Therapeutics, Inc. | 71.0% | 217% | 0.89 |

### What diversifies REGN?

Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions).

- Moving a fifth of the money in REGN into SPMO would have cut the portfolio's volatility by 20% over the past 5 years and raised its annual return (+4.8% for REGN alone, +9.1% for the mix).
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of REGN over the past 5 years, with correlations of 0.24 or lower, and each still earned a positive 5-year return.
- FIX made money in six of the ten calendar years in which REGN lost money.

| Investment | Correlation with REGN | 5Y return | Volatility | Sharpe | Rose in REGN's 10 down years |
| --- | --- | --- | --- | --- | --- |
| LVHI: Franklin International Low Volatility High Dividend Index ETF | 0.24 | +119% | 11.1% | 1.48 | 1 of 10 |
| DXJ: WisdomTree Japan Hedged Equity Fund | 0.05 | +225% | 19.1% | 1.34 | 2 of 10 |
| EMLP: First Trust North American Energy Infrastructure Fund | 0.10 | +101% | 14.5% | 1.04 | 2 of 10 |
| HDV: iShares Core High Dividend ETF | 0.26 | +83.3% | 13.0% | 1.00 | 2 of 10 |
| [SMH](https://easycompare.io/research/smh): VanEck Semiconductor ETF | -0.09 | +323% | 36.9% | 0.97 | 3 of 10 |
| DBEF: Xtrackers MSCI EAFE Hedged Equity ETF | 0.13 | +85.0% | 13.8% | 0.96 | 2 of 10 |
| [GLD](https://easycompare.io/research/gld): SPDR Gold Shares | 0.02 | +126% | 18.9% | 0.96 | 3 of 10 |
| SPMO: Invesco S&P 500 Momentum ETF | -0.06 | +136% | 20.8% | 0.93 | 2 of 10 |

## Common questions

### What was REGN's worst drawdown?

REGN's deepest decline since it began trading in 1991 was 91.8%, from February 2000 to April 2005. It took about six years from the low to climb back to its old high.

### What were REGN's best and worst years?

Over 29 full calendar years, REGN's best year was 2012, when it returned 209%. Its worst was 1997, with a return of -46.9%.

### Is there a better investment than REGN?

Among REGN's popular alternatives, AMGN, GILD and VRTX earned more than REGN with less volatility over the past 5 years. AMGN returned 19.6% a year at 24.9% volatility, against 7.7% a year at 31.1%. Looking beyond its popular alternatives, MRK (pharmaceuticals) and TAK (pharmaceuticals) earned more than REGN with less volatility over the past 5 years. MRK returned 16.3% a year at 24.8% volatility, against 7.7% a year at 31.1%.

### Is REGN more volatile than the S&P 500?

Yes. REGN's volatility over the past 5 years was 31.1%, 1.8 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, REGN's return lands within 31.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.

### What is REGN's Sharpe ratio?

REGN's Sharpe ratio over the past 5 years was 0.40, against 0.79 for the S&P 500, so REGN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.

### How correlated is REGN with the S&P 500?

Over the past 5 years, REGN's monthly returns had a correlation of 0.08 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are close to unrelated, or move in opposite directions, so it can steady a stock portfolio. In the table, the correlation column measures each option against REGN instead: the lower it is, the more that option would diversify a REGN holding.

### What are the best alternatives to REGN?

Of the 22 popular alternatives we compared, seven outperformed REGN in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: HALO, AMGN and LLY.

### Did REGN outperform the S&P 500?

REGN finished ahead of the S&P 500 (SPY) in 17 of 29 full calendar years. In 2025, it returned +9.0%, against +17.7% for the index.

### How did REGN do in stock market crashes?

REGN fell less than the S&P 500 (SPY) in four of the ten major crashes it has traded through, and further in six. The clearest case was the 2015 China and oil sell-off, when REGN fell 37.7% and the S&P 500 fell 12.8%.

### What diversifies REGN?

These had a low correlation with REGN over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.24), DXJ (correlation 0.05) and EMLP (correlation 0.10); among large stocks, CAH (correlation 0.11), CLS (correlation -0.10) and FIX (correlation -0.04). A correlation near zero means the two have moved largely independently.

## More research

- [Amgen (AMGN) Performance, Alternatives and Market Rank](https://easycompare.io/research/amgn)
- [Eli Lilly and Company (LLY) Performance, Alternatives and Market Rank](https://easycompare.io/research/lly)
- [Gilead Sciences (GILD) Performance, Alternatives and Market Rank](https://easycompare.io/research/gild)
- [Thermo Fisher Scientific (TMO) Performance, Alternatives and Market Rank](https://easycompare.io/research/tmo)
- [Vertex Pharmaceuticals (VRTX) Performance, Alternatives and Market Rank](https://easycompare.io/research/vrtx)
- [Danaher (DHR) Performance, Alternatives and Market Rank](https://easycompare.io/research/dhr)
- [argenx (ARGX) Performance, Alternatives and Market Rank](https://easycompare.io/research/argx)
- [Sanofi (SNY) Performance, Alternatives and Market Rank](https://easycompare.io/research/sny)
- [Schwab U.S. Dividend Equity ETF (SCHD) Performance, Alternatives and Market Rank](https://easycompare.io/research/schd)
- [NVIDIA (NVDA) Performance, Alternatives and Market Rank](https://easycompare.io/research/nvda)
- [Apple (AAPL) Performance, Alternatives and Market Rank](https://easycompare.io/research/aapl)
- [Alphabet (GOOG) Performance, Alternatives and Market Rank](https://easycompare.io/research/goog)

## Explore further

- Full page with charts: https://easycompare.io/research/regn
- All research pages: https://easycompare.io/llms.txt
- Compare the entire market against REGN live: https://betterthanspy.com/?b=REGN&utm_source=easycompare&utm_medium=research